SEC Form 4 · accession 0001214659-18-000287
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher S Henney
Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 9, 2018 · 6:32 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.65 | Jan 5, 2018 | A | 84,705 | A | — | Jan 5, 2028 | Common Stock | 84,705 | 84,705 | D |
| Stock Option (right to buy)F2 | $1.65 | Jan 5, 2018 | A | 84,705 | A | — | Jan 5, 2028 | Common Stock | 84,705 | 84,705 | D |
Explanation of responses
- F1This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017.
- F2This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018.